Equities research analysts at StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) in a research note issued to investors on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Performance
The firm has a market cap of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85. The firm has a 50 day simple moving average of $0.14. Nabriva Therapeutics has a 12 month low of $1.22 and a 12 month high of $8.45.
Nabriva Therapeutics Company Profile
Featured Articles
- Five stocks we like better than Nabriva Therapeutics
- What is the FTSE 100 index?
- High-Yield Texas Instruments Could Hit New Highs Soon
- How to invest in marijuana stocks in 7 steps
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- What Investors Need to Know About Upcoming IPOs
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.